Sign Up Today and Learn More About Synthekine Stock
Invest in or calculate the value of your shares in Synthekine or other pre-IPO companies through EquityZen's platform.
Synthekine Stock
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
About Synthekine Stock
Founded
2018
Headquarters
Menlo Park, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Synthekine Press Mentions
Stay in the know about the latest news on Synthekine
Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in First‑Line Nonsquamous NSCLC with Features of Immunotherapy Resistance
biospace • Mar 18, 2026
Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in First‑Line Nonsquamous NSCLC with Features of Immunotherapy Resistance
morningstar • Mar 18, 2026
MSD announces results from Keytruda combination trial for RCC
clinicaltrialsarena • Mar 03, 2026
Synthekine and MSD collaborate for STK-012 combination trial to treat NSCLC
clinicaltrialsarena • Feb 28, 2026
Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors
pharmiweb • Feb 23, 2026
Synthekine Management
Leadership team at Synthekine
Chief Executive Officer
Debanjan Ray
Board Member
Julie Papanek Grant
Join now and verify your accreditation status to gain access to:
- Synthekine Current Valuation
- Synthekine Stock Price
- Synthekine Management
- Available deals in Synthekine and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Synthekine Cap Table and Funding History by Share Class and Liquidity Preferences
- Synthekine Revenue and Financials
- Synthekine Highlights
- Synthekine Business Model
- Synthekine Risk Factors
- Synthekine Research Report from SACRA Research
Trading Synthekine Stock
How to invest in Synthekine stock?
Accredited investors can buy pre-IPO stock in companies like Synthekine through EquityZen funds. These investments are made available by existing Synthekine shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Synthekine stock?
Shareholders can sell their Synthekine stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
